Awakn Life Sciences

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) in which it calls for an additional phase 3 trial to further evaluate its safety and efficacy. As Psychiatric Times...

For people suffering from any type of addiction, getting the best medical care can make a significant difference in their journey to recovery. In the case of alcohol abuse, for example, the talk about care has become more critical because America’s addiction crisis seemed to deepen partly...

Awakn Life Sciences Corp. (OTCQB: AWKNF) reported it secured funding from Innovate UK to identify the quickest and most cost-effective route to market in both the U.K. and the U.S. for its lead program — Project Kestrel, proprietary ketamine-assisted therapy for treating Alcohol Use Disorder...

Photo by Adrien Converse on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. In recent years the medical community has reportedly become more aware of the potential benefits psychedelic drugs have...

Photo by Tranava University on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Could Ketamine be a key ingredient in the treatment of behavioral disorders?  The team at Awakn Life Sciences...

Awakn Life Sciences (OTCQB: AWKNF) has announced the successful completion of the first ketamine study for a varied set of behavioral addictions. The study, led by Awakn's head of ketamine-assisted therapy, Prof. Celia Morgan was focused on investigating the effects of ketamine when...

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States, one biotech company specializing in new addiction therapeutics is developing its presence in Europe...

Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder. When founded, Awakn's stated goal was to treat different types of addictions through the use of psychedelics....

Photo by Myriam Zilles on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Addiction, whether it's substance addiction to alcohol or illicit drugs, or behavioural...

A number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: ATAI) last week. Ratings ranged from a sober sector performance rating from RBC Capital Markets with a $19 12-month price target to a bullish Overweight rating from Cantor Fitzgerald,...

Awakn Life Sciences Corp. (NEO: AWKN) has officially announced the launch of a research program studying the use of ketamine in substance abuse disorder and behavioral addictions. In a recent interview with Benzinga, Anthony Tennyson, CEO of the UK-based company, explained how Awakn’s...

Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS.”  The company had an...

Awakn Life Sciences Corp. (NEO: AWKN), a biotech company that develops psychedelics treatments for addiction, began trading on the NEO exchange last week. The company is directing much of its efforts toward building an infrastructure to provide Ketamine and MDMA treatment for patients struggling...

Global Developments in Germany, Canada and Brazil Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression. Dr. Gerhard Gründer, of the Central Institute of Mental Health Mannheim, will lead the study alongside the Department of Psychiatry and...